Search Results

You are looking at 111 - 120 of 512 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Ten Years of Progress in Colon Cancer Therapy

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Locally Recurrent Endometrial Cancer: A Case Report

Srinivas K. Tantravahi, and Theresa L. Werner

pathologically staged as FIGO stage IA (pT1a pN0 Mx). She received no adjuvant therapy. She returned 3 months later with recurrent vaginal bleeding. A 2-cm friable mass was visualized at the apex of the vaginal cuff on pelvic examination and was resected

Full access

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

. 29. Gunderson LL Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy . Int J Radiat Oncol Biol Phys 1982 ; 8 : 1

Full access

Take Your Medicine

Harold J. Burstein

percentage. Of course, a few caveats are warranted. The bulk of these reports are derived from studies of women taking adjuvant therapy for hormone receptor-positive breast cancer. Such patients often have a favorable prognosis and might reasonably be

Full access

Management of a Patient With Advanced BRAF-Mutant Melanoma

Michelle T. Ashworth and Adil Daud

and MEK inhibitors, and effective adjuvant therapies can be expected to increase the impact of accurate staging with SLNB on overall survival. At the time of metastasis to lymph nodes in 2002, the patient was treated with complete lymphadenectomy

Full access

Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma

Yongzhu He, Laihui Luo, Renfeng Shan, Junlin Qian, Lifeng Cui, Zhao Wu, Shuju Tu, WenJian Zhang, Wei Lin, Hongtao Tang, Zeyu Huang, Zhigang Li, Shengping Mao, Hui Li, Zemin Hu, Liping Liu, Wei Shen, Kun He, and Yong Li

-based calculator for the postoperative nomogram to better distinguish patients in different risk levels and predict DFS and OS. In recent years, whether high-risk patients prone to early tumor recurrence should receive postoperative adjuvant therapy has become a

Full access

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Kari Kendra, Jayanthi Lea, Nita Lee, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole McMillian, and Sara Espinosa

(SLN) biopsy or ipsilateral IF lymphadenectomy; the latter should be performed if no SLN(s) is/are detected. Adjuvant therapy is informed by primary tumor risk factors and nodal surgical pathology. Patients with anterior or posterior central vulvar

Full access

Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer

Ami Vyas, S. Suresh Madhavan, Usha Sambamoorthi, Xiaoyun (Lucy) Pan, Michael Regier, Hannah Hazard, and Sita Kalidindi

, radiotherapy (RT), and adjuvant therapy. 2 – 6 Regardless of these extensive costs to Medicare, there is insufficient up-to-date information on healthcare utilization and costs incurred by specific services, and factors significantly contributing to these

Full access

Routine Use of Zoledronic Acid in Early-Stage Breast Cancer

Kathleen Harnden and Kimberly Blackwell

recent prospective trial to date evaluating zoledronic acid in addition to standard adjuvant therapy in ESBC. 21 At the final efficacy analysis after a median follow-up Table 1 Characteristics of Published Phase III Trials With Zoledronic Acid

Full access

Adolescent and Young Adult Colorectal Cancer

Joleen M. Hubbard and Axel Grothey

% of patients undergoing total colectomy will have 5 or more bowel movements per day, and 30% will have issues with fecal incontinence. 34 , 35 Adjuvant Therapy for Stage II and III Colon Cancer Patients with high-risk stage II and III disease